Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 308 for your search:
Drug:
doxorubicin hydrochloride
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma
Phase:
Phase IV, Phase III
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
GPOH-NB2004
, EU-20661, NCT00410631
2.
Prevention of Cyclophosphamide, Hydroxydaunorubicin (Adriamycin), Oncovin (Vincristine), Prednisone/Prednisolone (CHOP)-Induced Chronic Cardiotoxicity
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
15 to 70
Sponsor:
Other
Protocol IDs:
OLSG-0401
, NCT00162955
3.
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL01
, NCT00198991
4.
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL03
, NCT00199004
5.
Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
Over 15
Sponsor:
Other
Protocol IDs:
GMALL05
, NCT00199082
6.
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 to 75
Sponsor:
Other
Protocol IDs:
CGC05MK1002
, NCT00188149
7.
EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children
Phase:
Phase IV
Type:
Treatment
Status:
Approved-not yet active
Age:
6 months to 21 years
Sponsor:
Other
Protocol IDs:
SHEBA-06-4013-IK-CTIL
, NCT00339118
8.
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 45
Sponsor:
Other
Protocol IDs:
0501-37
, NCT00352872
9.
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 60
Sponsor:
Other
Protocol IDs:
Hemato INCAN 01/2007
, NCT00429065
10.
Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
2006-003750-23
, LINFOTARGAM, NCT00466258
11.
German Multicenter Trial for the Treatment of Newly Diagnosed T-Lymphoblastic Lymphoma in Adults
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL04
, NCT00199017
12.
Yunzhi as Dietary Supplement in Breast Cancer
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
YUNZHI-BC
, NCT00647075
13.
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
TaCyDexVMP7
, NCT00652041
14.
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
UARK 2003-26
, NCT00090493
15.
Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 59
Sponsor:
Other
Protocol IDs:
N06IAA
, NCT00448266
16.
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 80
Sponsor:
Other
Protocol IDs:
A-39/29.1.2007
, ICMR No-5/8/7/26/99-ECD-I, NCT00522405
17.
Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
NCI
Protocol IDs:
SWOG-S9704
, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
18.
Phase III Randomized Study of Dexamethasone Versus Prednisolone During Induction Therapy and Prolonged Versus Conventional Duration Asparaginase During Consolidation and Late Intensification Therapy in Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
EORTC-58951
, NCT00003728
19.
Phase III Randomized Study of Induction and Maintenance Chemotherapy Regimens With Different Doses and Schedules of Methotrexate From the Berlin-Frankfurt-Munster-K2 Protocol With or Without Vinblastine in Children With Anaplastic Large Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 22
Sponsor:
Other
Protocol IDs:
FRE-IGR-ALCL99
, EU-20031, NHL2000/06, NCT00006455
20.
Phase III Randomized Study of Standard Induction Chemotherapy Comprising Vincristine, Dactinomycin, Ifosfamide, and Etoposide Followed By Consolidation Chemotherapy Comprising Vincristine, Dactinomycin, and Ifosfamide Versus High-Dose Busulfan and Melphalan Followed By Autologous Peripheral Blood Stem Cell Support With or Without Radiotherapy and/or Surgery in Patients With Tumor of the Ewing's Family
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 50
Sponsor:
NCI, Other
Protocol IDs:
EURO-EWING-INTERGROUP-EE99
, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, NCT00020566, AEWS0331
21.
Phase III Randomized Study of Adjuvant Induction Chemotherapy With or Without Cyclophosphamide and Methotrexate as Maintenance Chemotherapy in Patients With Stage I, II, or III Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
IBCSG-22-00
, EU-20119, NCT00022516, EUDRACT-2005-005666-36
22.
Phase III Randomized Study of Consolidation Therapy With or Without Strontium Chloride Sr 89 After Induction Chemotherapy in Patients With Androgen-Independent Prostate Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
MDA-ID-00156
, NCI-3410, 3410, NCT00024167
23.
Phase III Randomized Study of Response-Based Chemotherapy With Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, and Cyclophosphamide With or Without Dexamethasone, Etoposide, Cytarabine, Cisplatin, and/or Radiotherapy in Children With Newly Diagnosed Intermediate-Risk Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
NCI
Protocol IDs:
COG-AHOD0031
, NCT00025259, AHOD0031
24.
Phase III Randomized Study of Immediate Versus Deferred Adjuvant Chemotherapy After Radical Cystectomy in Patients With Stage III or IV Transitional Cell Carcinoma of the Bladder Urothelium
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
NCI, Other
Protocol IDs:
EORTC-30994
, ACOSOG-EORTC-30994, CAN-NCIC-EORTC-30994, FNCLCC-GETUG-EORTC-30994, NORDIC-EORTC-30994, UKCCCR-EORTC-30994, NCRI-BLADDER-EORTC-30994, NCT00028756
25.
Phase III Randomized Study of Two Different Schedules of Adjuvant Cyclophosphamide and Doxorubicin Versus Paclitaxel in Women With Operable Breast Cancer and 0-3 Positive Axillary Lymph Nodes
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-40101
, NCT00041119
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
